CanSinoBIO's Convidecia™ Approved as Heterologous Booster in China - Press Release

TIANJIN, China, Feb. 19, 2022 /CNW/ -- CanSino Biologics Inc. ("CanSinoBIO") (SSE: 688185, HKEX: 06185) today announced that its Recombinant Novel Cor

Related Keywords

Mexico ,Malaysia ,Kyrgyzstan ,Tianjin ,China ,Hungary ,Argentina ,Ecuador ,Chile ,Indonesia ,Pakistan ,Chinese , ,Cansino Biologics Inc ,Key Laboratory Of Pathogenic Microbiology ,Groupc Meningococcal Conjugate Vaccine ,World Health Organization ,Ministry Of Health Argentina ,Jiangsu Provincial Center ,Cansino Biologics ,Recombinant Novel Coronavirus Vaccine ,Adenovirus Type ,Joint Prevention ,Control Mechanism ,State Council ,Disease Control ,Pathogenic Microbiology ,Chinese Academy ,Conjugate Vaccine ,Sino Biologics ,